EUCTR2010-024354-11-AT进行中（未招募）不适用
Preoperative induction chemotherapy in combination with Bevacizumab followed by combined chemoradiotherapy in locally advanced rectal cancer with high risk of recurrence- phase II pilot study with preoperative administration of Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin) followed by Capecitabine (Xeloda) plus Radiotherapy (RTx)
ABCSG (Austrian Breast & Colorectal Cancer Study Group)0 个研究点目标入组 25 人开始时间: 2011年1月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18-80 years
- •Histologic confirmation of rectal andenocarcinoma stage cT3 (= 5mm to the mesorectal fascia)/cT4( primary curative intention)NxM0
- •No former chemotherapy, no former radiotherapy of the pelvic, no former tumour resection of a rectal carcinoma
- •General condition WHO grade 0-2
- •Adequate bone marrow reserve ( leucocytes =3 000/µl, thrombocytes =100 000/µl)
- •Adequate renal function (creatinine = 1,5 mg/dl, creatinine clearence > 50ml/min (Cockroft and Gault formula))
- •Adequate liver function (bilirubin =1,5x ULN, GOT and GPT =3,5x ULN)
- •Exclusion of pregnancy for women with childbearing potential (negative pregnancy test urine or serum)
- •Female patients with childbearing potential and male patients that are not surgically sterile must be practicing a medically acceptable contraceptive regimen while on study treatment until 3 months after the end of the study (e.g. oral contraceptives, condom, intrauterine device)
- •Life expectancy of at least 3 months
- •INR and aPTT = 1,5 x LLN
- •Provision of signed informed consents before registration
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Rectal carcinoma stage cT3 (> 5mm from the mesorectal fascia) all stages •Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin
- •General contraindication or known hypersensitivity against Bevacizumab, Capecitabine and Oxaliplatin
- •Not malignant diseases for which treatment with radiotherapy, resection of the rectum and treatment with chemotherapy (Bevacizumab, Capecitabine) is contraindicated:
- •uncontrolled hypertension (systolic > 150 mmHG and/or diastolic > 100 mmHG) or clinically significant (e.g. active) cardiovascular diseases: CVA (cardiovascular accident)/ apoplectic insult (= 6 months prior to registration), myocardial infarction (= 6 months prior to registration), unstable angina pectoris, CHF(congestive heart failure) with NYHA (New York heart Association) Grade II or higher, cardiac arrhythmia requiring therapy, hepatic diseases, significant neurologic or psychiatric disorders
- •Florids, serious infection at registration
- •Peripheral neuropathy (NCI CTCAE v 4.0 = grade 1)
- •Juridically limited contractual capability, indication of neurological or psychiatric disease which constrains upon investigators opinion the patients capability to adhere to the study routines
- •Major surgical procedure within 28 days prior start of the study, open wounds
- •Significant traumatic injury, bone fracture, unhealed wounds
- •Patients with spinal cord compression or metastases in the central nervous system
- •Indication of bleeding diathesis or coagulopathy
- •Intake of anticoagulant or thrombolytic agents and/or Aspirin > 325 mg/d within 10 days prior to registration
- •Current or recent (within 10 days prior to treatment start) therapy with full dosed anticoagulants. Preventive therapy is allowed.
- •Previous thromboembolic or haemorrhagic events within 6 months prior to registration
- •Previous abdominal fistulas, gastro-intestinal perforation or intra-abdominal abscesses within 6 months prior to registration
- •Treatment with another investigational drug within 28 days prior to registration
- •Patients with malabsorbtion syndrome or difficulties in swallowing
- •Indication of poor compliance of the patient
- •Pregnant or breast-feeding women
- •Proteinuria: Dipstick <2+. If the Dipstick is =2+ protein has to be estimated in the 24 hours urine. The value should not be higher then 1g/24 hours.
研究者
相似试验
招募中
2 期
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study2024-517183-31-00Centro Di Riferimento Oncologico Di Aviano93
已完成
1 期
Preoperative chemoradiation therapy combined with peptide vaccination for T3-pancreatic cancer: prospective phase I/II studyT3(UICC)-pancreatic cancerJPRN-UMIN000004422Department of Gastroenterological Surgery, Osaka Medical Center for cancer & Cardiovascular Diseases50
进行中（未招募）
不适用
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana
已完成
1 期
Phase I study of pre-operative combination therapy with Mogamulizumab (anti-CCR4) and Nivolumab (anti-PD-1) against solid cancer patientsGastric cancer, esophageal cancer, lung cancer, renal cancer and oral cancer patients who are scheduled to have the first standard operationJPRN-UMIN000021480Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University16
进行中（未招募）
不适用
Preoperative combined radiochemotherapy for patients with newly diagnosed, primary operable and locally advanced rectal carcinoma (cT3, Nx, M0) of the lower and middle rectum - Studie R02 (95)ocally advanced rectal carcinoma (cT3, Nx, M0) of the lower and middle rectum.EUCTR2004-002358-72-ATAustrian Breast and Colorectal Cancer Study Group (ABCSG)60